Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences to Present at Upcoming Scientific Meetings
08:00am, Wednesday, 01'st Oct 2025
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
08:00am, Thursday, 25'th Sep 2025
CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, wil
SEATTLE--(BUSINESS WIRE)--Kinea Bio Inc., a biotechnology company dedicated to developing transformative genetic medicines, today announced two major achievements in its gene therapy program: a commit
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
08:00am, Tuesday, 23'rd Sep 2025
- Non-exclusive license for Solid's proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio's gene therapy for dysferlin-related limb-girdle muscular dystrophy -
Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript
04:28pm, Tuesday, 02'nd Sep 2025
Solid Biosciences Inc. (NASDAQ:SLDB ) Citi's Biopharma Back to School Conference September 2, 2025 1:45 PM EDT Company Participants Alexander Cumbo - President, CEO & Director Conference Call Particip
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Thursday, 28'th Aug 2025
CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
04:07pm, Tuesday, 12'th Aug 2025
- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 01'st Aug 2025
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to ad
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
03:02pm, Friday, 11'th Jul 2025
Solid Biosciences is approaching key catalysts in DMD gene therapy, with SGT-003 showing promising early safety and efficacy signals. The evolving DMD landscape, especially safety concerns with compet
PHILADELPHIA , July 10, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating Solid Biosciences Inc. (NASDAQ: SLDB) on behalf of the company's shareholders. Since S
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Desi
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 01'st Jul 2025
CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Tuesday, 03'rd Jun 2025
CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
08:00am, Wednesday, 28'th May 2025
CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neurom
